GARIBALDI, BRUNO
 Distribuzione geografica
Continente #
NA - Nord America 280
EU - Europa 171
AS - Asia 99
AF - Africa 53
SA - Sud America 23
OC - Oceania 1
Totale 627
Nazione #
US - Stati Uniti d'America 277
IT - Italia 108
SG - Singapore 64
CI - Costa d'Avorio 39
IE - Irlanda 38
CN - Cina 29
BR - Brasile 22
SN - Senegal 12
FI - Finlandia 8
BE - Belgio 4
DE - Germania 3
RU - Federazione Russa 3
CA - Canada 2
GB - Regno Unito 2
HK - Hong Kong 2
IN - India 2
NG - Nigeria 2
NL - Olanda 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
JP - Giappone 1
PL - Polonia 1
TR - Turchia 1
Totale 627
Città #
Santa Clara 89
Singapore 48
Chicago 41
Abidjan 39
Dublin 36
Ashburn 25
Chandler 18
Civitanova Marche 17
Boardman 14
Dakar 12
Catania 7
Florence 6
Hefei 6
Naples 5
Palermo 5
Piazzola Sul Brenta 5
Brussels 4
Cambridge 4
Helsinki 4
Lawrence 4
Los Angeles 4
Rome 4
Bari 3
Lappeenranta 3
Piacenza 3
Santa Venerina 3
Seattle 3
Abuja 2
Aci Sant'Antonio 2
Amsterdam 2
Andover 2
Belo Horizonte 2
Frankfurt am Main 2
Hong Kong 2
Kochi 2
Melilli 2
Milan 2
New York 2
Orvieto 2
San Francisco 2
São Paulo 2
Turin 2
Washington 2
Ancona 1
Augusto Corrêa 1
Barcellona Pozzo di Gotto 1
Boston 1
Brejo Santo 1
Buenos Aires 1
Capão da Canoa 1
Chelyabinsk 1
Concepción de la Vega 1
Des Moines 1
Elesbão Veloso 1
Francisco Beltrão 1
Gatchina 1
Gioiosa Marea 1
Goiânia 1
Gravatá 1
Lagoa do Itaenga 1
Lentini 1
London 1
Melbourne 1
Messina 1
Modica 1
Montes Claros 1
Munich 1
Ningbo 1
Olomouc 1
Paracatu 1
Passa e Fica 1
Pelotas 1
Perm 1
Piraju 1
Praia Grande 1
Rio de Janeiro 1
San Giovanni la Punta 1
Santa Maria 1
Santos 1
The Dalles 1
Tokyo 1
Tremestieri Etneo 1
Turku 1
Warsaw 1
Wilmington 1
Woodbridge 1
Totale 487
Nome #
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 67
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 65
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 57
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 57
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 54
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 49
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 48
Multiple Myeloma in 2023 Ways: From Trials to Real Life 43
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 43
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes 43
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association 40
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study 39
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 25
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 12
Totale 642
Categoria #
all - tutte 3.254
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.254


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202231 0 0 0 0 6 4 3 1 6 3 0 8
2022/2023120 4 4 4 3 8 15 5 23 29 11 10 4
2023/2024180 13 21 14 19 6 36 7 24 0 2 24 14
2024/2025311 6 63 14 30 71 36 18 9 17 19 28 0
Totale 642